They want your blood

“The Verge article exposes a growing trend in the U.S. health‑tech sector where companies are monetizing personal blood data under the promise of extended longevity and predictive health insights. In the U.S., this model taps into a booming direct‑to‑consumer (DTC) diagnostics market projected to reach $10 billion by 2030, raising questions about data privacy, regulatory oversight, and the ethics of commodifying biological samples. Consumers may face higher out‑of‑pocket costs for subscription‑based panels, while insurers could use the data to adjust premiums or coverage. The trend also fuels a competitive race among tech giants, startups, and biotech firms to secure proprietary health‑data pipelines, potentially reshaping the U.S. healthcare ecosystem. Expert Analysis: This shift signals a convergence of wearables, AI, and genomics that could democratize health monitoring but also intensify data‑ownership disputes. If regulators tighten data‑protection rules, companies may pivot to more transparent consent models, altering the competitive dynamics in the DTC diagnostics market.”